Articles by G. Steven Burrill

publications@b-c.com

Chief Executive Officer at Burrill & Company

Financing Innovation
April 1, 2013
By: G. Steven Burrill

Early-stage companies are finding alternatives to venture capital.

Accelerating Change Marks 2012 for Life Sciences
January 1, 2013
By: G. Steven Burrill

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

Recent Therapeutics IPOs Outshine Market, but Performance Mixed for Broader Life-Sciences Issues
October 1, 2012
By: G. Steven Burrill

A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.

Pharmaceutical Dealmaking Broadens its Partnering Base
July 1, 2012
By: G. Steven Burrill

Collaborative R&D models coincide with new ways to fund translational research.

A Strong Start to 2012
April 1, 2012
By: G. Steven Burrill

Better news about the global economy buoys life-sciences funding.

Global Economic Woes Overshadow Biotech Industry Advances in 2011
January 1, 2012
By: G. Steven Burrill

Greater emphasis on focus and efficiency for companies as market demands value in 2012.

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
October 1, 2011
By: G. Steven Burrill

Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings

Biotech Posts Strong Gains
July 1, 2011
By: G. Steven Burrill

Strong pipelines, approvals, and deals drive up market cap.

Biotech Starts the Year Positively
April 1, 2011
By: G. Steven Burrill

Industry starts the year with a positive spin.